OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first dosing of a patient in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study. OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at multiple UK cancer centres beginning this month. Enadenotucirev has shown potent, broad-spectrum, anti-cancer activity pre-clinically and is also in phase I/II clinical trials in patients with colorectal tumours.
Help employers find you! Check out all the jobs and post your resume.
